Neurizon Therapeutics (ASX: NUZ & NUZOA) announced positive results from a preclinical study of its lead candidate, NUZ-001, in amyotrophic lateral sclerosis (ALS).
The company states that NUZ-001 reduces the aggregation of key ALS disease target, TDP-43. TDP-43 aggregation is a key hallmark pathological feature of ALS.
“The positive results from these preclinical studies are a significant milestone, providing validation of our hypothesis that NUZ-001 and its major metabolite prevent the damaging accumulation of TDP-43 in diseased neuronal cells. This finding also highlights the power of NUZ-001 to improve neuronal electrophysiology, an essential step towards providing patients with ALS with a meaningful treatment option,” said Dr. Michael Thurn, managing director and CEO of Neurizon.
